NewAmsterdam Pharma Co N.V. (NAMS): Total Liabilities
$85.85M
As of 2025-12-31
$73.03M
As of 2026-06-30
+21.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.85M | -19.9% | 2026-02-18, Balance as of period end |
| 2024-12-31 | $107.12M | +82.5% | 2026-02-18, Balance as of period end |
| 2023-12-31 | $58.70M | +21.2% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $48.43M | n/a | 2024-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $7.11M | +1.6% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $15.78M | +7.4% |
Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗